EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7–9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was inve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Franceschi, Enrico, Stupp, Roger, van den Bent, Martin J., van Herpen, Carla, Laigle Donadey, Florence, Gorlia, Thierry, Hegi, Monika, Lhermitte, Benoit, Strauss, Lewis C., Allgeier, Anouk, Lacombe, Denis, Brandes, Alba A.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3499012/
https://ncbi.nlm.nih.gov/pubmed/23090987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars